Efficacy of NS-718, a novel lipid nanosphere-encapsulated amphotericin B, against Cryptococcus neoformans

Antimicrobial Agents and Chemotherapy

Volumn 42, Issue 7, 1998, Pages 1722-1725

  Hossain, Mohammad Ashraf ^a   Maesaki, Shigefumi ^a   Kakeya, Hiroshi ^a   Noda, Tetsuhiro ^a   Yanagihara, Katsunori ^a   Sasaki, Eisuke ^a   Hirakata, Yoichi ^a   Tomono, Kazunori ^a   Tashiro, Takayoshi ^a   Kohno, Shigeru ^a  

^a NAGASAKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B DERIVATIVE; AMPHOTERICIN B LIPID COMPLEX; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIFUNGAL ACTIVITY; ARTICLE; CRYPTOCOCCOSIS; DRUG EFFICACY; DRUG FORMULATION; DRUG MEGADOSE; LUNG MYCOSIS; MALE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 0031807491     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.42.7.1722     Document Type: Article

References (19)

1. Brajtburg, J., and J. Bolard. 1996. Carrier effects on biological activity of amphotericin B. Clin. Microbiol. Rev. 9:512-531.
2. Brajtburg, J., S. Elberg, S. J. Travis, and G. S. Kobayashi. 1994. Treatment of murine candidiasis and cryptococcosis with amphotericin B incorporated into egg lecithin-bile salt mixed micelles. Antimicrob. Agents Chemother. 38: 294-299.
3. Chen, S. C. A., M. Muller, J. Z. Zhou, L. C. Wright, and T. C. Sorrel. 1997 Phospholipase activity in Cryptococcus neoformans: a new virulence factor? J. Infect. Dis. 175:414-120.
4. Espuelas, M. S., P. Legrand, J. M. Irache, C. Gamazo, A. M. Orecchioni, J. P. Devissaguet, and P. Ygartua. 1997. Poly(ε-caprolacton) nanoparticles as an alternative way to reduce amphotericin B toxicity. Int. J. Pharm. 158:19-27.
5. Fukui, H., T. Koike, A. Saheki, S. Sonoke, H. Yoshikawa, H. Sasaki, Y. Tomii, and J. Seki. 1996. A novel antifungal drug delivery system: lipid nano-sphere incorporating amphotericin B (LNS-AmB), abstr. 5026, p. 655. In Proceedings of the 23rd International Symposium on Controlled Release of Bioactive Materials, Kyoto, Japan.
6. Granich, G. G., G. S. Kobayashi, and D. J. Krogstad. 1986. Sensitive high-pressure liquid chromatographic assay for amphotericin B which incorporates an internal standard. Antimicrob. Agents Chemother. 29:584-588.
7. Graybill, J. R., P. C. Craven, R. L. Taylor, D. M. Williams, and W. E. Magee. 1982. Treatment of murine cryptococcosis with liposome-associated amphotericin B. J. Infect. Dis. 145:748-752.
8. Hay, R. J. 1994. Liposomal amphotericin B, AmBisome. J. Infect. 1:35-43.
9. Hiemenz, J. W., and T. J. Walsh. 1996. Lipid formulations of amphotericin B: recent progress and future directions. Clin. Infect. Dis. 22(Suppl. 2):S133-144.
10. Hostetler, J. S., K. V. Clemons, L. H. Hanson, and D. A. Stevens. 1992. Efficacy and safety of amphotericin B colloidal dispersion compared with those of amphotericin B deoxycholate suspension for treatment of disseminated murine cryptococcosis. Antimicrob. Agents Chemother. 36:2556-2560.
11. Kakeya, H., H. Udono, N. Ikuno, Y. Yamamoto, K. Mitsutake, T. Miyazaki, K. Tomono, H. Koga, T. Tashiro, E. Nakayama, and S. Kohno. 1997. A 77-kilodalton protein of Cryptococcus neoformans, a member of the heat shock protein family, is a major antigen detected in the sera of mice with pulmonary cryptococcosis. Infect. Immun. 65:1653-1658.
12. Kawakami, K., X. Qifeng, M. Tohyama, M. H. Qureshi, and A. Saito. 1996. Contribution of tomour necrosis factor-alpha (TNF-α) in host defence mechanism against Cryptococcus neoformans. Clin. Exp. Immunol. 106:468-474.
13. Kohno, S., T. Otsubo, K. Hara, Y. Tomii, and J. Seki. 1995. A new antifungal drug delivery system, lipid nano-sphere encapsulated amphotericin B (LNS-AmB), its evaluation in the rat model of invasive pulmonary aspergillosis, abstr. F109, p. 131. In Program and Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
14. Savoy, A. C., D. M. Lupan, P. B. Manalo, J. S. Roberts, A. M. Schlageter, L. C. Weinhold, and T. R. Kozel. 1997. Acute lethal toxicity following passive immunization for treatment of murine cryptococcosis. Infect. Immun. 65: 1800-1807.
15. Seki, J., H. Sasaki, M. Doi, H. Yoshikawa, Y. Tanaka, S. Yamane, H. Fukui, S. Sonoke, H. Yamamoto, M. Hirose, Y. Ezure, T. Ando, K. Ushimaru, and M. Sugiyama. 1994. Lipid nano-sphere (LNS), a protein-free analogue of lipoproteins, as a novel drug carrier for parenteral administration IV. J. Control Release 28:352-353.
16. Sharkey, P. K., J. R. Graybill, E. S. Johnson, S. G. Hausrath, R. B. Pollard, A. Kolokathis, D. Mildvan, P. Fan-Havard, R. H. K. Eng, T. F. Patterson, J. C. Pottage, Jr., M. S. Simberkoff, J. Wolf, R. D. Meyer, R. Gupta, L. W. Lee, and D. S. Gordon. 1996. Amphotericin B lipid complex compared with amphotericin B in the treatment of cryptococcal meningitis in patients with AIDS. Clin. Infect. Dis. 22:315-321.
17. Stevens, D. A. 1994. Overview of amphotericin B colloidal dispersion (amphocil). J. Infect. 1:45-49.
18. Tanaka, K., T. Miyazaki, S. Maesaki, K. Mitsutake, H. Kakeya, Y. Yamamoto, K. Yanagihara, M. A. Hossain, T. Tashiro, and S. Kohno. 1996. Detection of Cryptococcus neoformans gene in patients with pulmonary cryptococcosis. J. Clin. Microbiol. 34:2826-2828.
19. Yamaguchi, H., K. Uchida, H. Kume, T. Shinoda, K. Watanabe, T. Kusunoki, M. Hiruma, and H. Ishizaki. 1994. Report of the committee of clinical laboratory standards. Jpn. J. Med. Mycol. 36:61-86.